Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide and Cholecalciferol in MDS
NCT00104806Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Nov 2004
- Primary completion
- Jan 2006
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide and vitamin d in myelodysplastic syndrome (MDS), sponsored by Wake Forest University Health Sciences. Primary endpoints: Complete response rate at 6 months, Rate of hematological improvement at 6 months and 1 more. Started Nov 2004; status: terminated.
02
Drugs
arsenic trioxidevitamin d
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00104806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00104806.